EU’s ‘Significant Benefit’ Metric For Orphan Drugs Still A Thorn In Industry’s Side

Ipsen’s Bylvay is one of six medicines that the European Medicines Agency has said should be stripped of their orphan drug designation over the last three years, leading the company to criticize the agency’s approach to “significant benefit” assessments.